Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI North America CPhI North America
Not Confirmed
Not Confirmed
20-22 May, 2025
AACR Annual meetingAACR Annual meeting
Not Confirmed
Not Confirmed
25-30 April, 2025
AOCS Annual MeetingAOCS Annual Meeting
Not Confirmed
Not Confirmed
27-30 April, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI North America CPhI North America
Industry Trade Show
Not Confirmed
20-22 May, 2025
AACR Annual meetingAACR Annual meeting
Industry Trade Show
Not Confirmed
25-30 April, 2025
AOCS Annual MeetingAOCS Annual Meeting
Industry Trade Show
Not Confirmed
27-30 April, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/our-unmatched-efficiency-and-track-record-of-faster-dmf-filings-give-our-customers-a-critical-competitive-advantage
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/top-pharma-companies-drugs-in-2024-merck-s-keytruda-maintains-top-spot-as-novo-s-semaglutide-nips-at-its-heels
25 Apr 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250425808169/en/Verastem-Oncology-Announces-%2475-million-Private-Placement
23 Apr 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250423863470/en/Verastem-Oncology-Announces-U.S.-IND-Clearance-of-VS-7375-Oral-KRAS-G12D-ONOFF-Inhibitor-Enabling-Phase-12a-Trial-in-Advanced-Solid-Tumors
25 Mar 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250325480582/en/Verastem-Oncology-Announces-Multiple-Presentations-Focused-on-RASMAPK-Pathway-Inhibition-at-AACR-Annual-Meeting-2025
20 Mar 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250320781501/en/Verastem-Oncology-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Highlights-Recent-Business-Updates
20 Feb 2025
// BUSINESSWIRE
29 Jan 2025
// BUSINESSWIRE
Details:
The proceeds from the financing are expected to fund the potential launch of VS-6766 (avutometinib) and defactinib in recurrent low-grade serous ovarian cancer.
Lead Product(s): Avutometinib,Defactinib
Therapeutic Area: Oncology Brand Name: VS-6766
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: RTW Investments
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 25, 2025
Lead Product(s) : Avutometinib,Defactinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : RTW Investments
Deal Size : $75.0 million
Deal Type : Private Placement
Verastem Oncology Announces $75 million Private Placement
Details : The proceeds from the financing are expected to fund the potential launch of VS-6766 (avutometinib) and defactinib in recurrent low-grade serous ovarian cancer.
Product Name : VS-6766
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 25, 2025
Details:
VS-7375 is an oral KRAS G12D (on/off) inhibitor, small molecule drug candidate, which is being evaluated for the treatment of advanced solid tumors.
Lead Product(s): GFH375
Therapeutic Area: Oncology Brand Name: VS-7375
Study Phase: Phase I/ Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 23, 2025
Lead Product(s) : GFH375
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Verastem gets IND Clearance for KRAS Inhibitor VS-7375 in Solid Tumors
Details : VS-7375 is an oral KRAS G12D (on/off) inhibitor, small molecule drug candidate, which is being evaluated for the treatment of advanced solid tumors.
Product Name : VS-7375
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 23, 2025
Details:
The financing aims to advance the clinical development of company's lead product, VS-6766 (Avutometinib) plus defactinib. It is being evaluated for the KRAS mutant low-grade serous ovarian cancer.
Lead Product(s): Avutometinib,Defactinib
Therapeutic Area: Oncology Brand Name: VS-6766
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Oberland Capital Management
Deal Size: $157.5 million Upfront Cash: Undisclosed
Deal Type: Financing January 13, 2025
Lead Product(s) : Avutometinib,Defactinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Oberland Capital Management
Deal Size : $157.5 million
Deal Type : Financing
Verastem Oncology Announces Debt Refinancing, Partnership for Ovarian Cancer
Details : The financing aims to advance the clinical development of company's lead product, VS-6766 (Avutometinib) plus defactinib. It is being evaluated for the KRAS mutant low-grade serous ovarian cancer.
Product Name : VS-6766
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 13, 2025
Details:
Combination of avutometinib, a RAF/MEK clamp, and defactinib, a selective FAK inhibitor, being development for adults with recurrent KRAS mutant low-grade serous ovarian cancer.
Lead Product(s): Avutometinib,Defactinib
Therapeutic Area: Oncology Brand Name: VS-6766
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 30, 2024
Lead Product(s) : Avutometinib,Defactinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Verastem Oncology Announces FDA Acceptance Of Avutometinib + Defactinib NDA
Details : Combination of avutometinib, a RAF/MEK clamp, and defactinib, a selective FAK inhibitor, being development for adults with recurrent KRAS mutant low-grade serous ovarian cancer.
Product Name : VS-6766
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 30, 2024
Details:
Combination of avutometinib, a RAF/MEK clamp with sotorasib & defactinib, , being developed for the treatment of KRAS G12C mutant non-small cell lung cancer.
Lead Product(s): Avutometinib,Defactinib,Sotorasib
Therapeutic Area: Oncology Brand Name: VS-6766
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 18, 2024
Lead Product(s) : Avutometinib,Defactinib,Sotorasib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Verastem Oncology Provides Clinical Update on RAMP 203 Trial in KRAS G12C Mutant NSCLC
Details : Combination of avutometinib, a RAF/MEK clamp with sotorasib & defactinib, , being developed for the treatment of KRAS G12C mutant non-small cell lung cancer.
Product Name : VS-6766
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 18, 2024
Details:
The collaboration aims to support the advancement of the clinical development of VS-7375/GFH375 in china, which is being evaluated in the treatment of KRAS G12D-mutant solid tumors.
Lead Product(s): VS-7375
Therapeutic Area: Oncology Brand Name: VS-7375
Study Phase: Phase I/ Phase IIProduct Type: Other Small Molecule
Sponsor: GenFleet Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 07, 2024
Lead Product(s) : VS-7375
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : GenFleet Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Verastem Doses First Patient with GFH375/VS-7375 in Phase 1/2 Trial in China
Details : The collaboration aims to support the advancement of the clinical development of VS-7375/GFH375 in china, which is being evaluated in the treatment of KRAS G12D-mutant solid tumors.
Product Name : VS-7375
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 07, 2024
Details:
Combination of avutometinib, a RAF/MEK clamp, and defactinib, a selective FAK inhibitor, being development for adults with recurrent KRAS mutant low-grade serous ovarian cancer.
Lead Product(s): Avutometinib,Defactinib
Therapeutic Area: Oncology Brand Name: VS-6766
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 31, 2024
Lead Product(s) : Avutometinib,Defactinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Verastem Submits NDA for Avutometinib + Defactinib in KRAS-Mutant Ovarian Cancer
Details : Combination of avutometinib, a RAF/MEK clamp, and defactinib, a selective FAK inhibitor, being development for adults with recurrent KRAS mutant low-grade serous ovarian cancer.
Product Name : VS-6766
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 31, 2024
Details:
Combination of avutometinib, a RAF/MEK clamp, and defactinib, a selective FAK inhibitor, being development for adult patients with pancreatic ductal adenocarcinoma.
Lead Product(s): Avutometinib,Defactinib
Therapeutic Area: Oncology Brand Name: VS-6766
Study Phase: Phase I/ Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 29, 2024
Lead Product(s) : Avutometinib,Defactinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Verastem Receives FDA Orphan Designation for Avutometinib in Pancreatic Cancer
Details : Combination of avutometinib, a RAF/MEK clamp, and defactinib, a selective FAK inhibitor, being development for adult patients with pancreatic ductal adenocarcinoma.
Product Name : VS-6766
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 29, 2024
Details:
The net proceeds from the public offering to fund the potential launch ofVS-6766 (avutometinib) and Defactinib in LGSOC & also continuing clinical research and development of other product candidates.
Lead Product(s): Avutometinib,Defactinib
Therapeutic Area: Oncology Brand Name: VS-6766
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Guggenheim Securities
Deal Size: $55.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 23, 2024
Lead Product(s) : Avutometinib,Defactinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Guggenheim Securities
Deal Size : $55.0 million
Deal Type : Public Offering
Verastem Oncology Announces Pricing of $55M Public Offering of Stock and Warrants
Details : The net proceeds from the public offering to fund the potential launch ofVS-6766 (avutometinib) and Defactinib in LGSOC & also continuing clinical research and development of other product candidates.
Product Name : VS-6766
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 23, 2024
Details:
Combination of avutometinib, a RAF/MEK clamp, and defactinib, a selective FAK inhibitor, being development for adult patients with recurrent KRAS mutant (KRAS mt) low-grade serous ovarian cancer.
Lead Product(s): Avutometinib,Defactinib
Therapeutic Area: Oncology Brand Name: VS-6766
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 24, 2024
Lead Product(s) : Avutometinib,Defactinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Verastem Oncology Begins NDA Submission for Avutometinib & Defactinib Combination
Details : Combination of avutometinib, a RAF/MEK clamp, and defactinib, a selective FAK inhibitor, being development for adult patients with recurrent KRAS mutant (KRAS mt) low-grade serous ovarian cancer.
Product Name : VS-6766
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 24, 2024
ABOUT THIS PAGE